How Artificial Intelligence Can Enhance Epilepsy Management

By Staff Writer

February 13, 2024

Introduction

The application of artificial intelligence (AI) in healthcare is increasingly becoming a topic of interest, especially to detect diseases from pathology samples or imaging. In recognition of World Epilepsy Week, we take a look at 4 studies on developments made in AI use in epilepsy research and innovation, discussing how these may lead to improved outcomes for those living with one of the most common neurological disorders.

AI and Epilepsy Detection

The first study by Jin et al. discusses the use of machine learning in detecting Focal Cortical Dysplasia (FCD), a major cause of pharmacoresistant epilepsy in those undergoing surgical resection. The use of magnetic resonance imaging (MRI) is mostly used to detect these features, however, some FCD type II lesions are too subtle to be detected by conventional MRI scans. Finding a previously undiscovered lesion may change the surgical technique and improve seizure results. Using surface-based MRI morphometry coupled with machine learning, they were able to detect FCD with a sensitivity of 73.7% and specificity of 90.0% in this study. This method showed robust performance across different centres and scanners, suggesting AI’s potential as a valuable tool in presurgical evaluations for patients with pharmacoresistant epilepsy.

AI in Classifying Temporal Lobe Epilepsy

The second study explored in depth the use of AI in classifying Temporal Lobe Epilepsy (TLE). Gleichgerrcht et al. used support vector machine (SV) and deep learning (DL) models based on region of interest (ROI-based) structural and diffusion brain MRI data. The models showed better or similar (68–75%) performance in identifying TLE compared to lateralizing the side of TLE. The models performed more accurately for patients with hippocampal sclerosis (68–76%) than non-lesional patients (53–62%). Overall, the study demonstrated the potential of machine learning and AI in future epilepsy care, especially in TLE.

AI for Epileptic Seizure Prediction

The third study, Daoud and Bayoumi examined the use of deep learning in predicting epileptic seizures. Patients who suffer from epilepsy will experience a significant impact on their lives if they are able to anticipate the onset of seizures.The researchers developed a patient-specific seizure prediction technique based on deep learning and applied to long term scalp electroencephalogram (EEG). Four deep learning models were suggested as a method to improve classification accuracy and prediction time by extracting the most discriminative characteristics. The suggested method uses the convolutional neural network (CNN) to extract significant spatial data to predict seizures earlier than current methods. This approach yielded a high accuracy of 99.6% and a very early seizure prediction time, making it one of the most efficient methods for seizure prediction.

AI for Intracranial Interictal Epileptiform Discharges Detection

In the final study Quon and colleagues explored the use of deep learning in classifying intracranial interictal epileptiform discharges (IEDs). Epileptiform discharges that occur between seizures are known as IEDs and is also used in differentiating epilepsy types. Previous research has linked IEDs to memory loss, increased seizure frequency and recurrence, making IEDs clinically relevant. Human visual annotation of IEDs is the gold standard, however it takes time and training to classify EEG patterns correctly. The researchers developed an automated method, “AiED,” which combined a template-matching algorithm and a CNN. The method achieved comparable performance to human reviewers, suggesting its potential in supporting clinical and research EEG analyses by reducing time and resources spent.

Concluding remarks:

In conclusion these studies demonstrate the potential of AI in improving the detection and management of epilepsy. This will lead to improved accuracy, lower capacity demand on healthcare services and overall better outcome for patients living with epilepsy. As AI technology continues to evolve, its application in epilepsy management is likely to become even more significant.

Reference url

Recent Posts

Fabhalta C3 glomerulopathy treatment
       

Fabhalta C3 glomerulopathy treatment Gains EMA Endorsement as First Targeted Therapy

💡 Have you heard the latest on treatment options for rare kidney diseases?

Novartis’ Fabhalta (iptacopan) has received a positive opinion from the EMA, potentially paving the way for the first approved treatment for C3 glomerulopathy. This first-in-class therapy showed a remarkable 35.1% reduction in proteinuria, promising improved outcomes for patients facing this progressive condition.

Curious about the implications for healthcare and the economy? Dive into the full article to learn how Fabhalta could reshape the landscape for patients with C3G and other complement-mediated diseases.

#SyenzaNews #HealthcareInnovation #DrugDevelopment #MarketAccess

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.